SCHEMBL3560372

SCHEMBL3560372

C/C(CN1C(=O)c2ccccc2C1=O)=C1\CCCN(C(=O)O)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
KMT2A Q03164 5/20 0.45
MEN1 O00255 3/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 6/20 0.44
HPGD P15428 3/20 0.44
HTT P42858 1/20 0.43
ACHE P22303 1/20 0.42
KDM4E B2RXH2 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 1/20 0.41
LMNA P02545 1/20 0.41
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564500 1.00 HSD17B10 (0.47) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL3132153 1.00 HSD17B10 (0.47) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL3133513 0.86 CA12 (0.48) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL3139368 0.85 CA12 (0.47) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL13315631 0.84 HSD17B10 (0.42) HSD17B10KMT2AMEN1GAAALDH1A1
SCHEMBL13315635 0.84 HSD17B10 (0.42) HSD17B10KMT2AMEN1GAAALDH1A1
SCHEMBL3135738 0.82 CA12 (0.43) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL3135746 0.82 CA12 (0.43) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL3135749 0.82 CA12 (0.43) HSD17B10CA12CA9KMT2AMEN1
SCHEMBL3124297 0.78 CA12 (0.47) HSD17B10CA12CA9KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861401-B1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2015-11-18 EP disclosed
US-7732612-B2 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones JANSSEN PHARMACEUTICA, N.V. (BE) 2010-06-08 US disclosed
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES JANSSEN PHARMACEUTICA NV (BE) 2009-06-18 US disclosed
US-20060052359-A1 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones JANSSEN PHARMACEUTICA, N.V. (BE) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052359-A1 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones NQO2, NQO1, REN HSD17B10 3364/4885CA12 3691/4885CA9 2020/4885
US-20090156577-A1 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES NQO2, QRFPR, NQO1 HSD17B10 3088/4885CA12 3602/4885CA9 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.